🇺🇸 FDA
Pipeline program

SIG001

2025YW315

Phase 1 mab active

Quick answer

SIG001 for Neoplams is a Phase 1 program (mab) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
First Tracks Biotherapeutics
Indication
Neoplams
Phase
Phase 1
Modality
mab
Status
active

Clinical trials